Strides Pharma ScienceNSE:STAR -2.62%67 Current Ratio is 1.25 as of Mar. 2026, which is 12% above its 10-year median of 1.12. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹773.22 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 998 Drug Manufacturers companies, Strides Pharma Science ranks worse than 74.15% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Strides Pharma Science's current ratio for the quarter that ended in Mar. 2026 was 1.25.
Strides Pharma Science has a current ratio of 1.25. It generally indicates good short-term financial strength.
The historical rank and industry rank for Strides Pharma Science's Current Ratio or its related term are showing as below:
NSE:STAR'
s Current Ratio Range Over the Past 10 Years
Min: 0.93 Med: 1.12 Max: 1.31
Current: 1.25
During the past 13 years, Strides Pharma Science's highest Current Ratio was 1.31. The lowest was 0.93. And the median was 1.12.
NSE:STAR's Current Ratio is ranked worse than 74.15% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs NSE:STAR: 1.25
Strides Pharma Science (NSE:STAR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Strides Pharma Science Current Ratio Related Terms
Strides Pharma Science Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Current Ratio distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strides Pharma Science (NSE:STAR) has a Current Ratio of 1.25 as of Mar. 2026. This is 12% above median its historical median of 1.12. Over the past decade, Strides Pharma Science's Current Ratio has ranged from 0.93 to 1.31. According to the industry distribution chart, Strides Pharma Science ranks #740 out of 998 companies in the Drug Manufacturers industry, placing it in the top 74.1%.
Is Strides Pharma Science's Current Ratio too high?
Strides Pharma Science's current Current Ratio of 1.25 is 12% above median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 1.31. The Drug Manufacturers industry median Current Ratio is 2.00. Strides Pharma Science's value of 1.25 is 37.3% below this industry median. Based on the distribution chart, Strides Pharma Science ranks #740 out of 998 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #740 out of 998 companies for Current Ratio. This places Strides Pharma Science in the lower half of its industry. The industry median Current Ratio is 2.00. Strides Pharma Science's value of 1.25 is 37.3% below this benchmark. Historically, Strides Pharma Science's own Current Ratio has ranged from 0.93 to 1.31 over the past decade. While the company's 10-year median is 1.12 vs. the industry median of 2.00, Strides Pharma Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current Current Ratio of 1.25 is 37.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current Current Ratio is 1.25, which is 12% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹773.22, compared to a current price of ₹1,082.20 — trading 40% above its estimated fair value. The current Current Ratio is 1.25, which is 12% above median its 10-year median of 1.12 and 37.3% below the Drug Manufacturers industry median of 2.00. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Current Ratio is 1.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,082.20 is trading 40% above its estimated GF Value™ of ₹773.22.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
Current Ratio: 1.25 (12% above median its 10-year median of 1.12)
GF Value™: ₹773.22 vs. price of ₹1,082.20 (40% above fair value)
Industry Position: 37.3% below the Drug Manufacturers median (#740 of 998)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score
Get the complete analysis for NSE:STAR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
